US Pharma MarketingICON audit finds overstated revenue; Secretome and Psilera raise cash
ICON audit found revenue was overstated in 2023 and 2024; Psilera and Secretome Therapeutics raise funds. Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push for in vivo therapies Drug pricing…
👀 ICON’s audit probe is complete: The investigation found that ICON’s revenue was overstated by $65.3 million in 2023 (about 0.8% of its total revenue that year) and by $92.7 million in 2024 (1.1% of ...
Source: Endpoints News